市場調查報告書

裘馨氏肌肉萎縮症(DMD)- 市場洞察,流行病學,市場預測

Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 602052
出版日期 內容資訊 英文 204 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
裘馨氏肌肉萎縮症(DMD)- 市場洞察,流行病學,市場預測 Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年01月01日內容資訊: 英文 204 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的裘馨氏肌肉萎縮症(DMD)2018年的患病數推算為3萬1,432人。美國擁有最大罹患數。歐盟5國法國的罹患數最大,其次是義大利。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的裘馨氏肌肉萎縮症(DMD)市場調查,總括性彙整市場概要,疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 主要洞察

第2章 裘馨氏肌肉萎縮症(DMD)市場概要

  • 裘馨氏肌肉萎縮症(DMD)的市場佔有率(實際成果值)
  • 裘馨氏肌肉萎縮症(DMD)的市場佔有率(預測值)

第3章 疾病背景和概要:裘馨氏肌肉萎縮症(DMD)

  • 簡介
  • 臨床症狀
  • 原因
    • 家族間的裘馨氏肌肉萎縮症的發生率
  • 裘馨氏肌肉萎縮症(DMD)的遺傳
    • 女性和DMD
  • 病理生理學
  • 生物標記
    • 組織結構
    • 遺傳基因標記
    • 蛋白質
    • 脂質與代謝物
    • 微型核糖核酸
  • 診斷
  • 病的進展

第4章 裘馨氏肌肉萎縮症(DMD):流行病學和患者人口

  • 主要調查結果
  • 主要7個國家整體患病數
  • 主要7個國家整體診斷數

第5章 裘馨氏肌肉萎縮症(DMD)的各國流行病學

  • 美國
    • 假設和理論的根據
    • 裘馨氏肌肉萎縮症(DMD)的整體患病數
    • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
    • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
    • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
    • 裘馨氏肌肉萎縮症(DMD)併發症的患病數
  • 歐盟5國
    • 德國
      • 裘馨氏肌肉萎縮症(DMD)的整體患病數
      • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
      • 裘馨氏肌肉萎縮症(DMD)併發症的患病數
    • 法國
      • 裘馨氏肌肉萎縮症(DMD)的整體患病數
      • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
      • 裘馨氏肌肉萎縮症(DMD)併發症的患病數
    • 義大利
      • 裘馨氏肌肉萎縮症(DMD)的整體患病數
      • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
      • 裘馨氏肌肉萎縮症(DMD)併發症的患病數
    • 西班牙
      • 裘馨氏肌肉萎縮症(DMD)的整體患病數
      • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
      • 裘馨氏肌肉萎縮症(DMD)併發症的患病數
    • 英國
      • 裘馨氏肌肉萎縮症(DMD)的整體患病數
      • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
      • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
      • 裘馨氏肌肉萎縮症(DMD)併發症的患病數
  • 日本
    • 裘馨氏肌肉萎縮症(DMD)的整體患病數
    • 裘馨氏肌肉萎縮症(DMD)的整體診斷數
    • 裘馨氏肌肉萎縮症(DMD)的診斷數:各年齡
    • 裘馨氏肌肉萎縮症(DMD)的診斷數:疾病類型
    • 裘馨氏肌肉萎縮症(DMD)併發症的患病數

第6章 治療方法

  • 裘馨氏肌肉萎縮症(DMD)的標準治療
    • 皮質類固醇
  • 治療方針
    • 基因治療
    • 使用肌肉前體細胞或幹細胞的細胞療法
    • 細胞骨骼蛋白質的膜穩定化/提高
    • 二次連鎖治療
  • 醫療管理
    • 矯正配料,支架,輪椅
    • 心臟照護
    • 攣縮
    • 用餐
    • 運動
    • 物理治療/作業療法
    • 呼吸系統照護
    • 脊椎彎曲
  • 支持療法
  • 心理社會管理

第7章 裘馨氏肌肉萎縮症(DMD)相關美國指南

  • 裘馨氏肌肉萎縮症(DMD)進展相關皮質類固醇的有效性
    • Prednisone
    • Deflazacort
  • 最適合的給藥計劃

第8章 未滿足需求

第9章 已上市治療藥

  • Emflaza:Marathon Pharmaceuticals/ PTC
    • 醫藥品概要
    • 法規的里程碑
    • 其他開發活動
    • 安全性和有效性
    • 產品簡介
  • Exondys 51:Sarepta Therapeutics
  • Translarna:PTC Therapeutics

第10章 新藥

  • 關鍵交叉競爭(後期新藥)
  • 關鍵交叉競爭(中期新藥)
  • Golodirsen:Sarepta Therapeutics
    • 醫藥品概要
    • 其他開發活動
    • 臨床開發
    • 產品簡介
  • Casimersen:Sarepta Therapeutics
  • Talditercept alfa:Roche
  • Idebenone:Santhera Pharmaceuticals
    • 安全性和有效性
  • Givinostat:Italfarmaco
  • Edasalonexent:Catabasis Pharmaceuticals
  • Viltolarsen:日本新藥
  • Vamorolone:Santhera Pharmaceuticals

第11章 市場分析裘馨氏肌肉萎縮症(DMD):主要7個國家

  • 主要調查結果
  • 主要7個國家裘馨氏肌肉萎縮症(DMD)的市場規模

第12章 美國市場預測

  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第13章 歐盟5國市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 整體市場規模
    • 市場規模:各治療藥物
  • 英國
    • 整體市場規模
    • 市場規模:各治療藥物

第14章 日本市場預測

  • 日本
    • 整體市場規模
    • 市場規模:各治療藥物

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

  • 調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0275

DelveInsight's 'Duchenne Muscular Dystrophy - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Duchenne Muscular Dystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Duchenne Muscular Dystrophy (DMD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Duchenne Muscular Dystrophy - Disease Understanding

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. Duchenne muscular dystrophy is a genetic disorder characterized by progressive muscle degeneration and weakness. It is one of nine types of muscular dystrophy.

DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3 and 5. The disease primarily affects boys, but in rare cases it can affect girls. DMD is inherited in an X-linked pattern, because the gene that can carry a DMD-causing mutation is on the X chromosome. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. DMD is classified as a dystrophinopathy. The dystrophinopathies are a spectrum of muscle diseases, each caused by alterations in the dystrophin gene. The most severe end of the spectrum is known as Duchenne muscular dystrophy lacking completely dystrophin protein.

The DelveInsight Duchenne Muscular Dystrophy (DMD) market report gives a thorough understanding of the Duchenne Muscular Dystrophy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Duchenne Muscular Dystrophy in the US, Europe, and Japan.

Duchenne Muscular Dystrophy Epidemiology

The Duchenne Muscular Dystrophy (DMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by diagnosed prevalent population, age-specific prevalent population, mutation-specific prevalent population and prevalent population of associated comorbidities in Duchenne Muscular Dystrophy.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Duchenne Muscular Dystrophy (DMD) was estimated to be 31,432 [7MM] in 2018. United States accounts for the highest DMD cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Duchenne Muscular Dystrophy, followed by Italy.

Duchenne Muscular Dystrophy Drug Chapters

This segment of the Duchenne Muscular Dystrophy report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. Treatments include the standard care for DMD along with the new upcoming therapeutic strategies including Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and Treatment of secondary cascades. Glucocorticoids, more precisely prednisone and deflazacort, form main drug treatment for DMD. Deflazacort is an oxazoline derivate of prednisone. Deflazacort shows more bone-sparing and carbohydrate-sparing properties with less weight-gain effects and improves strength and function. Therefore, Deflazacort becomes the preferred choice over prednisone due to limited side effects and the beneficial properties of muscle sparing and delayed scoliosis progression. The current US market possess only two approved products namely Emflaza and Exondys 51 commercialized by Marathon Pharmaceuticals/ PTC Therapeutics and Sarepta Therapeutics respectively. The recently approved products are known to capture the current market. Detailed chapters for all of these drugs, along with the upcoming therapies i.e., Golodirsen (SRP-4053, Sarepta Therapeutics), Talditercept alfa (also known as RO 6206, RO 7239361, BMS-986089), Idebenone (also known as Catena; CV-2619; Raxone) by Santhera Pharmaceuticals as well as another promising candidate i.e., Givinostat have been covered in the report.

Duchenne Muscular Dystrophy Market Outlook

The Duchenne Muscular Dystrophy (DMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Treatments include the standard care for DMD along with the new upcoming therapeutic strategies including Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and Treatment of secondary cascades. The medical management for Duchenne Muscular Dystrophy (DMD) comprises several aspects such as Cardiac care, Diet, Exercise, Respiratory Care, Braces, Spinal curvatures. The treatment strategy is also encompasses supportive treatment and Psychosocial management. DMD is a multilevel/multisystem disease. The medical care of a patient who has DMD and his family is not complete without support for their psychosocial wellbeing.

According to DelveInsight, the global market of Duchenne Muscular Dystrophy (DMD) was estimated to be USD 1,022 million in 2018. The United States accounts for the largest market size of Duchenne Muscular Dystrophy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, France had the highest market size with 84.15 Million in 2018, while Spain had the lowest market size of Duchenne Muscular Dystrophy (DMD). The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.

Duchenne Muscular Dystrophy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Duchenne Muscular Dystrophy (DMD). Owing to the positive outcomes of the several products during the developmental stage by key players such as Santhera Pharmaceutical, Catabasis Pharmaceuticals, Italfarmaco etc. has a potential to create a significant positive shift in the Duchenne Muscular Dystrophy (DMD) Market Size.  

Duchenne Muscular Dystrophy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Duchenne Muscular Dystrophy Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Duchenne Muscular Dystrophy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Duchenne Muscular Dystrophy market.
  • Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy market.
  • To understand the future market competition in the Duchenne Muscular Dystrophy market.

Table of Contents

1 Key Insights

2 Duchenne Muscular Dystrophy (DMD) Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of Duchenne Muscular Dystrophy (DMD) in 2017
  • 2.2 Market Share (%) Distribution of Duchenne Muscular Dystrophy (DMD) in 2028

3 Disease Background and Overview: Duchenne Muscular Dystrophy (DMD)

  • 3.1 Introduction
  • 3.2 Clinical Manifestations
  • 3.3 Causes
    • 3.3.1 Occurrence of Duchenne in Family
  • 3.4 Inheritance of DMD
    • 3.4.1 Females and DMD
  • 3.5 Pathophysiology
  • 3.6 Biomarkers
    • 3.6.1 Tissue Composition
    • 3.6.2 Genetic Makers
    • 3.6.3 Proteins
    • 3.6.4 Lipids and Metabolites
    • 3.6.5 MicroRNA
  • 3.7 Diagnosis
  • 3.8 Disease Progression

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2 7MM Total Patient Population of Duchenne Muscular Dystrophy (DMD)
  • 4.1 7MM Total Diagnosed Patient Population of Duchenne Muscular Dystrophy (DMD)

5 Country Wise-Epidemiology of Duchenne Muscular Dystrophy (DMD)

  • 5.1 United States
    • 5.1.1 Assumptions and Rationale
    • 5.1.2 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States
    • 5.1.3 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States
    • 5.1.4 Age- specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States
    • 5.1.5 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States
    • 5.1.6 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United States
  • 5.2 EU5 Countries
    • 5.2.1 Assumptions and Rationale
  • 5.3 Germany
    • 5.3.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany
    • 5.3.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany
    • 5.3.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany
    • 5.3.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany
    • 5.3.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Germany
  • 5.4 France
    • 5.4.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France
    • 5.4.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France
    • 5.4.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France
    • 5.4.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France
    • 5.4.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in France
  • 5.5 Italy
    • 5.5.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy
    • 5.5.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy
    • 5.5.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy
    • 5.5.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy
    • 5.5.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Italy
  • 5.6 Spain
    • 5.6.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain
    • 5.6.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain
    • 5.6.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain
    • 5.6.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain
    • 5.6.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Spain
  • 5.7 United Kingdom
    • 5.7.1 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
    • 5.7.2 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
    • 5.7.3 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
    • 5.7.4 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom
    • 5.7.5 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United Kingdom
  • 5.8 Japan
    • 5.8.1 Assumptions and Rationale
    • 5.8.2 Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan
    • 5.8.3 Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan
    • 5.8.4 Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan
    • 5.8.5 Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan
    • 5.8.6 Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Japan

6 Treatment

  • 6.1 Standard of care for DMD
    • 6.1.1 Corticosteroids
  • 6.2 Therapeutic Strategies
    • 6.2.1 Genetic Therapies
    • 6.2.2 Cell therapy using muscle precursor cells or stem cells
    • 6.2.3 Membrane stabilization and upregulation of cytoskeletal proteins
    • 6.2.4 Treatment of Secondary Cascades
  • 6.3 Medical Management
    • 6.3.1 Braces, standing frames and wheelchairs
    • 6.3.2 Cardiac Care
    • 6.3.3 Contractures
    • 6.3.4 Diet
    • 6.3.5 Exercise
    • 6.3.6 Physical and occupational therapy
    • 6.3.7 Respiratory Care
    • 6.3.8 Spinal Curvatures
  • 6.4 Supportive treatment for DMD
  • 6.5 Psychosocial management

7 United States Guideline on Duchenne Muscular Dystrophy (DMD)

  • 7.1 Efficacy of corticosteroids with regard to Duchenne muscular dystrophy (DMD) progression
    • 7.1.1 Prednisone
    • 7.1.2 Deflazacort
  • 7.2 Optimal dosing regimen
    • 7.2.1 Prednisone

8 Unmet Needs

9 Marketed Drugs

  • 9.1 Emflaza: Marathon Pharmaceuticals/ PTC Therapeutics
    • 9.1.1 Drug Description
    • 9.1.2 Regulatory Milestones
    • 9.1.3 Other Development Activities
    • 9.1.4 Safety and Efficacy
    • 9.1.5 Product Profile
  • 9.2 Exondys 51: Sarepta Therapeutics
    • 9.2.1 Drug Description
    • 9.2.2 Regulatory Milestones
    • 9.2.3 Other Development Activities
    • 9.2.4 Safety and Efficacy
    • 9.2.5 Product Profile
  • 9.3 Translarna: PTC Therapeutics
    • 9.3.1 Drug Description
    • 9.3.2 Regulatory Milestones
    • 9.3.3 Other Development Activities
    • 9.3.4 Safety and Efficacy
    • 9.3.5 Product Profile

10 Emerging Drugs

  • 10.1 Key Cross Competition (Late-Stage Emerging Drugs)
  • 10.2 Key Cross Competition (Mid-Stage Emerging Drugs)
  • 10.3 Golodirsen: Sarepta Therapeutics
    • 10.3.1 Product Description
    • 10.3.2 Other Development Activities
    • 10.3.3 Clinical Development
    • 10.3.4 Product Profile
  • 10.4 Casimersen: Sarepta Therapeutics
    • 10.4.1 Product Description
    • 10.4.2 Other Development Activities
    • 10.4.3 Clinical Development
    • 10.4.4 Product Profile
  • 10.5 Talditercept alfa: Roche
    • 10.5.1 Product Description
    • 10.5.2 Other Development Activities
    • 10.5.3 Clinical Development
    • 10.5.4 Product Profile
  • 10.6 Idebenone: Santhera Pharmaceuticals
    • 10.6.1 Product Description
    • 10.6.2 Other Development Activities
    • 10.6.3 Clinical Development
    • 10.6.4 Safety and Efficacy
    • 10.6.5 Product Profile
  • 10.7 Givinostat: Italfarmaco
    • 10.7.1 Product Description
    • 10.7.2 Other Development Activities
    • 10.7.3 Clinical Development
    • 10.7.4 Safety and Efficacy
    • 10.7.5 Product Profile
  • 10.8 Edasalonexent: Catabasis Pharmaceuticals
    • 10.8.1 Product Description
    • 10.8.2 Other Development Activities
    • 10.8.3 Clinical Development
    • 10.8.4 Safety and Efficacy
    • 10.8.5 Product Profile
  • 10.9 Viltolarsen: Nippon Shinyaku
    • 10.9.1 Product Description
    • 10.9.2 Other Development Activities
    • 10.9.3 Clinical Development
    • 10.9.4 Safety and Efficacy
    • 10.9.5 Product Profile
  • 10.1 Vamorolone: Santhera Pharmaceuticals
    • 10.10.1 Product Description
    • 10.10.2 Other Development Activities
    • 10.10.3 Clinical Development
    • 10.10.4 Safety and Efficacy
    • 10.10.5 Product Profile

11 Duchenne Muscular Dystrophy (DMD): 7 Major Market Analysis

  • 11.1 Key Findings
  • 11.2 Market Size of Duchenne Muscular Dystrophy (DMD) in 7MM

12 The United States Market Outlook

  • 12.1 United States Market Size
    • 12.1.1 Total Market size of Duchenne Muscular Dystrophy (DMD)
    • 12.1.2 Market Size by Therapies

13 EU-5 Countries: Market Outlook

  • 13.1 Germany
    • 13.1.1 Total Market size of Duchenne Muscular Dystrophy (DMD) in Germany
    • 13.1.2 Market Size by Emerging Therapies
  • 13.2 France
    • 13.2.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
    • 13.2.2 Market Size by Emerging Therapies
  • 13.3 Italy
    • 13.3.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
    • 13.3.2 Market Size by Emerging Therapies
  • 13.4 Spain
    • 13.4.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
    • 13.4.2 Market Size by Emerging Therapies
  • 13.5 United Kingdom
    • 13.5.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
    • 13.5.2 Market Size by Emerging Therapies

14 Japan: Market Outlook

  • 14.1 Japan market Size
    • 14.1.1 Total Market Size of Duchenne Muscular Dystrophy (DMD)
    • 14.1.2 Market Size by Emerging Therapies

15 Market Drivers

16 Market Barriers

17 Appendix

  • 17.1 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

  • Table 1: Total Population of Duchenne Muscular Dystrophy (DMD) in the 7MM (2017-2028)
  • Table 2: Total Diagnosed Population of Duchenne Muscular Dystrophy (DMD) in the 7MM (2017-2028)
  • Table 3: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Table 4: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Table 5: Age- specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Table 6: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Table 7: Prevalent Population of Associated Comorbidties in DMD in the United States (2017-2028)
  • Table 8: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Table 9: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Table 10: Age specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Table 11: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Table 12: Prevalent Population of Associated Comorbidties in DMD in Germany (2017-2028)
  • Table 13: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Table 14: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Table 15: Age specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Table 16: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Table 17: Prevalent Population of Associated Comorbidties in DMD in France (2017-2028)
  • Table 18: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Table 19: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Table 20: Age specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Table 21: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Table 22: Prevalent Population of Associated Comorbidties in DMD in Italy (2017-2028)
  • Table 23: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Table 24: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Table 25: Age - specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Table 26: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Table 27: Prevalent Population of Associated Comorbidties in DMD in Spain (2017-2028)
  • Table 28: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Table 29: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Table 30: Age - specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Table 31: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the UK (2017-2028)
  • Table 32: Prevalent Population of Associated Comorbidties in DMD in the UK (2017-2028)
  • Table 33: Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Table 34: Total Diagnosed Prevalent Population of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Table 35: Age - specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Table 36: Mutation specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Table 37: Prevalent Population of Associated Comorbidties in DMD in Japan (2017-2028)
  • Table 38: Comparison of Late-Stage emerging drugs under development
  • Table 39: Comparison of Late-Stage emerging drugs under development
  • Table 40: Clinical Trial Description
  • Table 41: Clinical Trial Description
  • Table 42: Clinical Trial Description
  • Table 43: Clinical Trial Description
  • Table 44: Clinical Trial Description
  • Table 45: Clinical Trial Description
  • Table 46: Clinical Trial Description
  • Table 47: Clinical Trial Description
  • Table 48: 7 Major Market Size of Duchenne Muscular Dystrophy (DMD) in USD Million (2017-2028)
  • Table 49: United States Market Size of Duchenne Muscular Dystrophy (DMD) in US, USD Million (2017-2028)
  • Table 50: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in United States, in USD Million (2017-2028)
  • Table 51: Market Size of Duchenne Muscular Dystrophy (DMD) in Germany, in USD Million (2017-2028)
  • Table 52: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in Germany, in USD Million (2017-2028)
  • Table 53: Market Size of Duchenne Muscular Dystrophy (DMD) in France, in USD Million (2017-2028)
  • Table 54: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in France, in USD Million (2017-2028)
  • Table 55: Market Size of Duchenne Muscular Dystrophy (DMD) in Italy, in USD Million (2017-2028)
  • Table 56: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in Italy, in USD Million (2017-2028)
  • Table 57: Market Size of Duchenne Muscular Dystrophy (DMD) in Spain, in USD Million (2017-2028)
  • Table 58: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in Spain, in USD Million (2017-2028)
  • Table 59: Market Size of Duchenne Muscular Dystrophy (DMD) in the UK, in USD Million (2017-2028)
  • Table 60: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in UK, in USD Million (2017-2028)
  • Table 61: Market Size of Duchenne Muscular Dystrophy (DMD) in Japan, in USD Million (2017-2028)
  • Table 62: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1: Cause of DMD
  • Figure 2: Inheritance of DMD
  • Figure 3: Biomarker types used for clinical management of DMD
  • Figure 4: Biomarker types used for clinical management of DMD
  • Figure 5: Total Diagnosed Patient Population of Duchenne Muscular Dystrophy (DMD) in the 7MM (2017-2028)
  • Figure 6: Total Diagnosed Patient Population of Duchenne Muscular Dystrophy (DMD) in the 7MM (2017-2028)
  • Figure 7: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Figure 8: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Figure 9: Age- Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Figure 10: Mutations Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United States (2017-2028)
  • Figure 11: Prevalent Population of Associated Comorbidties in DMD in the United States (2017-2028)
  • Figure 12: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Figure 13: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Figure 14: Age Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Figure 15: Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Figure 16: Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Germany (2017-2028)
  • Figure 17: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Figure 18: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Figure 19: Age- Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Figure 20: Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Figure 21: Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in France (2017-2028)
  • Figure 22: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Figure 23: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Figure 24: Age-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Figure 25: Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Figure 26: Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Italy (2017-2028)
  • Figure 27: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Figure 28: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Figure 29: Age - specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Figure 30: Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Figure 31: Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Spain (2017-2028)
  • Figure 32: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Figure 33: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Figure 34: Age- Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Figure 35: Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Figure 36: Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the United Kingdom (2017-2028)
  • Figure 37: Total Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Figure 38: Total Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Figure 39: Age - specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Figure 40: Mutation Specific Diagnosed Prevalence of Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Figure 41: Prevalent Population of Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in Japan (2017-2028)
  • Figure 42: Interdisciplinary management of DMD
  • Figure 43: Antisense-Mediated Exon Skipping
  • Figure 44: Unmet Needs of Duchenne Muscular Dystrophy (DMD)
  • Figure 45: 7 Major Market Size of Duchenne Muscular Dystrophy (DMD) in USD Million (2017-2028)
  • Figure 46: Market Size of Duchenne Muscular Dystrophy (DMD) in the United States, USD Millions (2017-2028)
  • Figure 47: Market size of Duchenne Muscular Dystrophy (DMD) by therapies in the US, in USD Million (2017-2028)
  • Figure 48: Market Size of Duchenne Muscular Dystrophy (DMD) in Germany, USD Million (2017-2028)
  • Figure 49: Market Size of Duchenne Muscular Dystrophy (DMD) by therapies, in Germany, in USD Million (2017-2028)
  • Figure 50: Market Size of Duchenne Muscular Dystrophy (DMD) in France, USD Million (2017-2028)
  • Figure 51: Market Size of Duchenne Muscular Dystrophy (DMD) by therapies, in France, in USD Million (2017-2028)
  • Figure 52: Market Size of Duchenne Muscular Dystrophy (DMD) in Italy, USD Million (2017-2028)
  • Figure 53: Market Size of Duchenne Muscular Dystrophy (DMD) by therapies in Italy, in USD Million (2017-2028)
  • Figure 54: Market Size of Duchenne Muscular Dystrophy (DMD) in Spain, USD Million (2017-2028)
  • Figure 55: Market Size of Duchenne Muscular Dystrophy (DMD) by therapies in Spain, in USD Million (2017-2028)
  • Figure 56: Market Size of Duchenne Muscular Dystrophy (DMD) in the UK, USD Million (2017-2028)
  • Figure 57: Market Size of Duchenne Muscular Dystrophy (DMD) by therapies in the UK, in USD Million (2017-2028)
  • Figure 58: Market Size of Duchenne Muscular Dystrophy (DMD) in Japan, USD Million (2017-2028)
  • Figure 59: Market Size of Duchenne Muscular Dystrophy (DMD) by therapies in Japan, in USD Million (2017-2028)
  • Figure 60: Market Drivers
  • Figure 61: Market Barriers
Back to Top